Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus (HSV) Eye Infection

Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes 
Simplex Virus (HSV) Eye Infection 
SAN DIEGO, CA -- (Marketwired) -- 09/09/13 --   Adamis
Pharmaceuticals Corporation (OTCQB: ADMP) today announced that a
recently published study conducted by university researchers found
that the company's antimicrobial and spermicidal agent, C31G, was
effective in treating Herpes Simplex Virus (HSV) in an eye infection
(ocular keratitis) animal model. Adamis previously reported that C31G
successfully completed a Phase 3 contraceptive clinical trial in
humans conducted by the National Institute of Child Health and Human
Dr. James M. Hill from Louisiana State University Health Science
Center and several other investigators demonstrated that in their
study C31G was effective in treating HSV in an animal model of eye
infection using live rabbits. The rabbit eye model utilized for the
study mimics the disease in humans. In the same study the researchers
also reported that ocular administration of C31G was safe and well
tolerated, confirming earlier clinical studies that established C31G
safety and tolerability in other applications. The study titled "The
antimicrobial agent C31G is effective for therapy for HSV-1 ocular
keratitis in the rabbit eye model" appears in the latest issue of the
scientific journal Antiviral Research. 
HSV-1 is the same virus that causes cold sores and is very common in
humans. It is estimated that as much as one-third of the world
population suffers from various forms of recurring HSV infections. In
the eye, it usually causes an infection of the cornea and that
infection is the most common cause of cornea-derived blindness.
Recent studies suggest that global incidence (rate of new disease) of
HSV keratitis is approximately 1.5 million new cases per year
including 40,000 cases of severe vision impairment or blindness. As
previous animal studies have shown, C31G is also active against
HSV-2, the cause of genital herpes. 
Adamis owns intellectual property relating to an antimicrobial and
contraceptive product candidate called C31G. C31G is an effective
spermicide and broad-spectrum antibacterial agent, which in previous
studies has shown activity against both gram-positive and
gram-negative organisms, including 
chlamydia, and a range of
antibiotic resistant strains. In considering commercialization
alternatives, the company intends to seek opportunities to partner
the commercialization of, or license the rights to develop and
commercialize, C31G with third parties that have a focus in the areas
of antimicrobials or contraception. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. In addition to
the C31G technology, Adamis currently has four product candidates in
its specialty pharmaceutical product pipeline, including the
Epinephrine Injection PFS syringe product for use in the emergency
treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of
asthma and chronic obstructive pulmonary disease, and APC-3000, an
HFA inhaled nasal steroid product for the treatment of allergic
rhinitis. The Company's biotechnology efforts are focused on the
development of therapeutic vaccine product candidates and cancer
drugs for patients with unmet medical needs in the multi-billion
dollar global cancer markets. Its products under research and
development include TeloB-VAX, a novel cell-based therapeutic cancer
vaccine and three drugs, APC-100, APC-200, and APC-300, for the
treatment of prostate cancer. 
Recent, previously-reported developments include the following: 

--  July 1 - Adamis announced the completion of a private placement with
    gross proceeds of $5.3 million.
--  August 6 - Adamis announced the exclusive license of a dry powder
    inhaler technology.
--  August 21 - Adamis announced that it had received an allowance in the
    United States for a patent application relating to one of its prostate
    cancer compounds

Forward Looking Statements 
This press release may contain forward-looking statements that relate
to future events or our future results of operations or future
financial performance, including, but not limited to the following
statements: the ability to fund future product development and
business operations; future revenues expected from any of the
company's product candidates, assuming that they are developed and
approved for marketing by the FDA and other regulatory authorities;
our ability to complete any future acquisitions of products, product
candidates or technologies; the intellectual property protection that
may be afforded by any patents or patent applications relating to the
company's technology; the results of any future preclinical or
clinical trials that may be conducted concerning the use of C31G for
the Herpes Simplex Virus or any other indication; and the interest of
any third party in entering into an arrangement with the Company
concerning the development, license, commercialization, or other
arrangements or agreements concerning C31G. In addition, provisions
in certain agreements to which the Company is a party provide for
significant payments to certain third parties upon marketing approval
by the FDA (or, in certain circumstances, certain foreign regulatory
authorities) of C31G for one or more indications, and payments to
other third parties in the event of sales or other revenues relating
to C31G or certain other events. There can be no assurances that we
will be able to successfully conclude a transaction involving C31G or
concerning the amounts that we might receive from any such
transaction, or that any C31G product will be submitted for
regulatory approval or will be approved or marketed. Certain of these
risks, uncertainties, and other factors are described in greater
detail in Adamis' filings from time to time with the SEC, which
Adamis strongly urges you to read and consider, all of which are
available free of charge on the SEC's web site at
Except as required by law, Adamis expressly disclaims any obligation
to update any forward-looking statements. 
Adamis Contacts 
Mark Flather
Director, Investor Relations & Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951 
Mark Gundy
Capital Group Communications, Inc.
(972) 240-1873 
Press spacebar to pause and continue. Press esc to stop.